keyword
MENU ▼
Read by QxMD icon Read
search

Breast diseases

keyword
https://www.readbyqxmd.com/read/29224163/methylation-sensitive-high-resolution-melting-ms-hrm
#1
Dianna Hussmann, Lise Lotte Hansen
Methylation-Sensitive High Resolution Melting (MS-HRM) is an in-tube, PCR-based method to detect methylation levels at specific loci of interest. A unique primer design facilitates a high sensitivity of the assays enabling detection of down to 0.1-1% methylated alleles in an unmethylated background.Primers for MS-HRM assays are designed to be complementary to the methylated allele, and a specific annealing temperature enables these primers to anneal both to the methylated and the unmethylated alleles thereby increasing the sensitivity of the assays...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29223987/radiosurgery-for-brain-metastases-changing-practice-patterns-and-disparities-in-the-united-states
#2
Benjamin H Kann, Henry S Park, Skyler B Johnson, Veronica L Chiang, James B Yu
Background: Management of brain metastases typically includes radiotherapy (RT) with conventional fractionation and/or stereotactic radiosurgery (SRS). However, optimal indications and practice patterns for SRS remain unclear. We sought to evaluate national practice patterns for patients with metastatic disease receiving brain RT. Methods: We queried the National Cancer Data Base (NCDB) for patients diagnosed with metastatic non-small cell lung cancer, breast cancer, colorectal cancer, or melanoma from 2004 to 2014 who received upfront brain RT...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223982/pazopanib-sensitivity-in-a-patient-with-breast-cancer-and-fgfr1-amplification
#3
Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, Shu-Jen Chen
Treatment options for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer and resistance to endocrine therapy remain limited. An interesting therapeutic target in these patients is fibroblast growth factor receptor 1 (FGFR1). FGFR1 is amplified in approximately 11% of patients with breast cancer, especially those with HR+ disease. This report presents a patient with metastatic HR+ HER2- breast cancer harboring an FGFR1 amplification who was resistant to endocrine therapy but responded to pazopanib, a multi-tyrosine kinase inhibitor with FGFR-inhibiting activity...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223797/clinical-impact-of-adjuvant-radiation-therapy-delay-after-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#4
Saulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, Kennya Medeiros Lopes de Barros Lima, Thiago Brasileiro de Freitas, Adriana Reis Brandão Matutino, Manoel Carlos Leonardi de Azevedo Souza, Renata Gondim Meira Velame de Azevedo, Pedro Antonio Hermida de Viveiros, Julianne Maria da Silva Lima, José Roberto Filassi, Heloísa de Andrade Carvalho, José Roberto Morales Piato, Max S Mano
BACKGROUND: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. MATERIAL AND METHODS: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: <8 weeks, 8-16 weeks and >16 weeks...
December 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29223745/buparlisib-plus-fulvestrant-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-progressing-on-or-after-mtor-inhibition-belle-3-a-randomised-double-blind-placebo-controlled-phase-3-trial
#5
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E Lønning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C G Tjan-Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT phosphorylation via a feedback activation pathway, potentially leading to resistance to mTOR inhibitors. We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrine therapy and mTOR inhibitors...
December 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29223481/can-breast-cancer-patients-with-her2-dual-equivocal-tumours-be-managed-as-her2-negative-disease
#6
Yiwei Tong, Xiaosong Chen, Xiaochun Fei, Lin Lin, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Kunwei Shen
BACKGROUND: Increasing human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC)/fluorescence in situ hybridisation (FISH) dual-equivocal breast tumours are reported after the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline update. The aim of this study is to investigate the clinico-pathologic characteristics, treatment patterns and disease outcome of these patients with HER2 dual-equivocal tumours. PATIENTS AND METHODS: Patients with HER2 IHC 2+ and available FISH results were retrospectively analysed from the Comprehensive Breast Health Center, Shanghai Ruijin Hospital...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29223479/long-term-efficacy-analysis-of-the-randomised-phase-ii-tryphaena-cardiac-safety-study-evaluating-pertuzumab-and-trastuzumab-plus-standard-neoadjuvant-anthracycline-containing-and-anthracycline-free-chemotherapy-regimens-in-patients-with-her2-positive-early
#7
Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, Javier Cortés
BACKGROUND: We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. METHODS: Descriptive efficacy analyses were conducted in patients randomised to group A (cycles 1-6: trastuzumab [8 mg/kg loading dose and 6 mg/kg maintenance] plus pertuzumab [840 mg loading dose and 420 mg maintenance], plus 5-fluorouracil, epirubicin and cyclophosphamide [FEC] [cycles 1-3; 500 mg/m2 5-fluorouracil/100 mg/m2 epirubicin/600 mg/m2 cyclophosphamide] then docetaxel [cycles 4-6; 75 mg/m2, escalated to 100 mg/m2 if well tolerated]), B (cycles 1-3: FEC, cycles 4-6: trastuzumab plus pertuzumab plus docetaxel as mentioned previously) or C (cycles 1-6: trastuzumab plus pertuzumab plus docetaxel [75 mg/m2, without dose escalation], and carboplatin [AUC 6]), five years after randomisation of the last patient...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29222623/tumor-infiltrating-lymphocytes-in-breast-cancer-patients-with-progressive-disease-during-neoadjuvant-chemotherapy
#8
Jacques Raphael, S Nofech-Mozes, T Paramsothy, N Li, S Gandhi
A minority of breast cancer (BC) patients progress during neoadjuvant chemotherapy (NCT). The aim of this study was to assess the value of Tumor infiltrating lymphocytes (TILs) in such a high-risk population where valid biomarkers are eagerly needed. A retrospective review identified BC patients who either progressed during NCT or achieved a pathologic complete response (pCR). An experienced BC pathologist semi-quantified stromal TILs in pre-treatment core biopsies using hematoxylin and eosin stained slides...
December 8, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29222540/validation-study-of-the-american-joint-committee-on-cancer-eighth-edition-prognostic-stage-compared-with-the-anatomic-stage-in-breast-cancer
#9
Anna Weiss, Mariana Chavez-MacGregor, Daphne Y Lichtensztajn, Min Yi, Audree Tadros, Gabriel N Hortobagyi, Sharon H Giordano, Kelly K Hunt, Elizabeth A Mittendorf
Importance: The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective: To perform a validation study of the AJCC eighth edition prognostic stage in a single-institution cohort and a large population database. Design, Setting, and Participants: Patients with breast cancer treated with surgery as an initial intervention were identified in a prospective institutional database from The University of Texas MD Anderson Cancer Center and the California Cancer Registry...
December 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29221345/a-rare-mixed-breast-cancer-of-intraductal-and-solid-papillary-with-tubular-carcinoma-histotypes-in-a-young-woman
#10
Xiaohui Zhang, Jie Shi, Yidong Zhou, Feng Mao, Yan Lin, Jinghong Guan, Zhiyong Liang, Qiang Sun
Mixed breast cancer, especially of uncommon breast cancer histotypes, is rare, limiting our understanding of the disease and influencing diagnostic and management outcomes. We report a case of mixed breast cancer, with features of intraductal and solid papillary and tubular carcinomas, which appeared in a young patient. Physical examination, ultrasonography, molybdenum target mammography, and histopathology were performed for a definitive diagnosis. Tumor resection followed by radiotherapy and adjuvant chemotherapy was selected as the therapeutic strategy, and the patient was followed up thrice post treatment...
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29221134/a-trna-fragment-trf5-glu-regulates-bcar3-expression-and-proliferation-in-ovarian-cancer-cells
#11
Kun Zhou, Kevin W Diebel, Jon Holy, Andrew Skildum, Evan Odean, Douglas A Hicks, Brent Schotl, Juan E Abrahante, Monique A Spillman, Lynne T Bemis
Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29221123/vegf-induced-intracellular-ca2-oscillations-are-down-regulated-and-do-not-stimulate-angiogenesis-in-breast-cancer-derived-endothelial-colony-forming-cells
#12
Francesco Lodola, Umberto Laforenza, Fabio Cattaneo, Federico Alessandro Ruffinatti, Valentina Poletto, Margherita Massa, Richard Tancredi, Estella Zuccolo, Dlzar Alì Khdar, Alberto Riccardi, Marco Biggiogera, Vittorio Rosti, Germano Guerra, Francesco Moccia
Endothelial colony forming cells (ECFCs) represent a population of truly endothelial precursors that promote the angiogenic switch in solid tumors, such as breast cancer (BC). The intracellular Ca2+ toolkit, which drives the pro-angiogenic response to VEGF, is remodelled in tumor-associated ECFCs such that they are seemingly insensitive to this growth factor. This feature could underlie the relative failure of anti-VEGF therapies in cancer patients. Herein, we investigated whether and how VEGF uses Ca2+ signalling to control angiogenesis in BC-derived ECFCs (BC-ECFCs)...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29220097/invasive-mucinous-carcinoma-of-the-breast-and-response-patterns-after-neoadjuvant-chemotherapy-nac
#13
Susan Fineberg, Rosemarie Didonato, Nella Shapiro, Tova Koenigsberg, Timothy D'Alfonso, Shabnam Jaffer
AIMS: Neoadjuvant chemotherapy (NAC) is often used to treat localized invasive breast cancer. Invasive mucinous carcinoma (IMC) is considered to be an indolent form of invasive breast cancer and is rarely treated with NAC. We report the largest series of IMC treated with NAC, and report a characteristic, but not well recognized, pattern of pathologic response. METHODS AND RESULTS: Our series included 7 patients with IMC treated with NAC. Three patients presented with locally advanced disease, three patients had tumors that were Her/2Neu positive, and four patients had tumors with admixed mucinous and micropapillary features...
December 8, 2017: Histopathology
https://www.readbyqxmd.com/read/29219189/breast-cancer-diagnosis-imaging-techniques-and-biochemical-markers
#14
REVIEW
Seyed Hamed Jafari, Zahra Saadatpour, Arash Salmaninejad, Fatemeh Momeni, Mojgan Mokhtari, Javid Sadri Nahand, Majid Rahmati, Hamed Mirzaei, Mojtaba Kianmehr
Breast cancer is a complex disease which is found as the second cause of cancer-associated death among women. Accumulating of evidence indicated that various factors (i.e. gentical and envirmental factors) could be associated with initiation and progression of breast cancer. Diagnosis of breast cancer patients in early stages is one of important aspects of breast cancer treatment. Among of various diagnosis platforms, imaging techniques are main diagnosis approaches which could provide valuable data on patients with breast cancer...
December 8, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29218898/building-trans-omics-evidence-using-imaging-and-omics-to-characterize-cancer-profiles
#15
Arunima Srivastava, Chaitanya Kulkarni, Parag Mallick, Kun Huang, Raghu Machiraju
Utilization of single modality data to build predictive models in cancer results in a rather narrow view of most patient profiles. Some clinical facet s relate strongly to histology image features, e.g. tumor stages, whereas others are associated with genomic and proteomic variations (e.g. cancer subtypes and disease aggression biomarkers). We hypothesize that there are coherent "trans-omics" features that characterize varied clinical cohorts across multiple sources of data leading to more descriptive and robust disease characterization...
2018: Pacific Symposium on Biocomputing
https://www.readbyqxmd.com/read/29217924/types-of-cancers-diagnosed-and-the-preference-of-families-of-adult-patients-with-cancer-about-disclosing-diagnosis-to-the-patients
#16
Engida Abebe, Hana Abebe
Background: Cancer has become one of the top causes of death in developing nations killing more people than the common infectious diseases do. For several reasons, disclosing cancer diagnosis to the patient is a challenging job for physicians and family members. Materials and Methods: A cross-sectional study was done to determine the common cancer diagnosis and the preference about disclosing cancer diagnosis to the patients among attendants of adult cancer patients seen at the regular surgical OPD of St...
May 2017: Ethiopian Journal of Health Sciences
https://www.readbyqxmd.com/read/29217907/synchronous-breast-cancer-and-gallbladder-diseases-a-chromosomal-analysis-a-pilot-study-at-a-tertiary-care-centre
#17
Devendra Chaudhary, Rahul Ahluwalia, Arvind Rai
Out of a total of 50 study-eligible patients, 15 patients were found to have synchronous breast cancer and gallbladder diseases. Fourteen such patients had breast cancer and cholelithiasis while 1 patient had breast cancer with gallbladder cancer. Amongst these 15 patients, 7 patients tested positive for chromosomal aberrations on karyotyping. Aberrations in these patients were seen on chromosomes 13 and 17 with 2 patients having deletion 13q, 2 having deletion 17q, and 2 having deletions on 17p while one patient had multiple deletions on chromosomes 13q and 17p...
December 2017: Indian Journal of Surgery
https://www.readbyqxmd.com/read/29217453/tumor-suppressing-effect-of-silencing-of-annexin-a3-expression-in-breast-cancer
#18
Ju-Yeon Kim, Eun Jung Jung, Hee Jin Park, Jeong-Hee Lee, Eun Jin Song, Seung-Jin Kwag, Ji-Ho Park, Taejin Park, Sang-Ho Jeong, Chi-Young Jeong, Young-Tae Ju, Young-Joon Lee, Soon-Chan Hong
INTRODUCTION: Annexin A3 (ANXA3) participates in various tumor-associated biological processes, including tumor initiation, progression, and metastasis. The present study was designed to investigate the expression and function of ANXA3 in breast cancer cells. MATERIALS AND METHODS: Annexin A3 protein expression in breast cancer cell lines was evaluated using Western blot analysis. ANXA3 expression in MDA-MB 231 breast cancer cells was silenced by RNA interference, and the effects of RNA silencing on cell proliferation, colony forming ability, wound-healing, and invasiveness were evaluated...
November 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29217193/regulation-of-inflammatory-gene-expression-in-macrophages-by-epithelial-stromal-interaction-1-epsti1
#19
Young-Hoon Kim, Jae-Rin Lee, Myong-Joon Hahn
Epithelial-stromal interaction 1 (EPSTI1) was first discovered as a gene induced in breast cancer epithelial cells by co-cultured stromal fibroblasts. There are many reports on the role of Epsti1 in cancer malignancy. Epsti1 is now well known in regulating cancer. Recently, the role of Epsti1 in the immune response has been reported; these reports suggest the role of Epsti1 in immune function, immune privilege, and autoimmune diseases. Furthermore, they show that Epsti1 is expressed in various types of immune cells...
December 4, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29216929/psat1-is-regulated-by%C3%A2-atf4-and-enhances-cell-proliferation-via-the-gsk3%C3%AE-%C3%AE-catenin-cyclin-d1-signaling-pathway-in-er-negative-breast-cancer
#20
Song Gao, Anqi Ge, Shouping Xu, Zilong You, Shipeng Ning, Yashuang Zhao, Da Pang
BACKGROUND: A growing amount of evidence has indicated that PSAT1 is an oncogene that plays an important role in cancer progression and metastasis. In this study, we explored the expression and function of PSAT1 in estrogen receptor (ER)-negative breast cancer. METHOD: The expression level of PSAT1 in breast cancer tissues and cells was analyzed using real-time-PCR (RT-PCR), TCGA datasets or immunohistochemistry (IHC). The overall survival of patients with ER-negative breast cancer stratified by the PSAT1 expression levels was evaluated using Kaplan-Meier analysis...
December 8, 2017: Journal of Experimental & Clinical Cancer Research: CR
keyword
keyword
51147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"